A European Registry Evaluating Symptomatic Effectiveness of Pharmacologically Treated Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Enlargement : Lessons Learned
(2021) In The Journal of urology 205(4). p.1145-1152- Abstract
PURPOSE: We evaluated unmet needs of lower urinary tract symptoms-benign prostatic enlargement pharmacological treatment by measuring symptom improvement, persistence and deterioration in real life. A prospective registry was conducted for 24 months in 5 European countries and analyzed by the European Association of Urology Research Foundation. MATERIALS AND METHODS: Previously untreated and treated patients were enrolled to the registry in both primary care and urology referral centers in France, Germany, Italy, Spain and the UK. RESULTS: Overall, 2,175 patients were enrolled with 1,838 analyzed, consisting of 575 previously untreated lower urinary tract symptoms-benign prostatic enlargement patients (no alpha blockers for at least 1... (More)
PURPOSE: We evaluated unmet needs of lower urinary tract symptoms-benign prostatic enlargement pharmacological treatment by measuring symptom improvement, persistence and deterioration in real life. A prospective registry was conducted for 24 months in 5 European countries and analyzed by the European Association of Urology Research Foundation. MATERIALS AND METHODS: Previously untreated and treated patients were enrolled to the registry in both primary care and urology referral centers in France, Germany, Italy, Spain and the UK. RESULTS: Overall, 2,175 patients were enrolled with 1,838 analyzed, consisting of 575 previously untreated lower urinary tract symptoms-benign prostatic enlargement patients (no alpha blockers for at least 1 month or no 5-alpha reductase inhibitors for at least 6 months) and 1,263 previously treated patients. During the registry 90% of patients adhered to the prescribed regimen. After 24 months, 70% of previously untreated and 42% of previously treated patients experienced symptom improvement (International Prostate Symptom Score [IPSS] reduction of ≥3 points). Symptomatic patients (IPSS ≥8) remained in both groups (59% in previously untreated and 61% in previously treated), with greater symptom deterioration (IPSS increase ≥3 points) in 18.9% in previously treated vs 7.8% in previously untreated patients. Both clinical lower urinary tract symptoms-benign prostatic enlargement progression and surgery rates were similar in untreated vs treated groups at 16% vs 17% and 5% vs 7%, respectively, at 24 months. CONCLUSIONS: This prospective registry confirmed lower urinary tract symptoms-benign prostatic enlargement pharmacological treatment effectiveness in a real-world setting, with low clinical progression observed in about 1 in 6 patients and lower surgery rates below 1 in 20, by 24 months.
(Less)
- author
- Tubaro, Andrea ; Speakman, Mark ; de la Taille, Alexandre ; Martínez-Piñeiro, Louis ; Berges, Richard ; Patel, Anup ; Bjartell, Anders LU ; Caris, Christien and Witjes, Wim
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- drug therapy, prostatic hyperplasia, registries
- in
- The Journal of urology
- volume
- 205
- issue
- 4
- pages
- 8 pages
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- scopus:85102722224
- pmid:33259270
- ISSN
- 1527-3792
- DOI
- 10.1097/JU.0000000000001506
- language
- English
- LU publication?
- no
- id
- c2e46d9f-f8f7-4e3f-87d2-1d9e89c6368c
- date added to LUP
- 2021-03-30 13:46:32
- date last changed
- 2025-10-20 15:17:09
@article{c2e46d9f-f8f7-4e3f-87d2-1d9e89c6368c,
abstract = {{<p>PURPOSE: We evaluated unmet needs of lower urinary tract symptoms-benign prostatic enlargement pharmacological treatment by measuring symptom improvement, persistence and deterioration in real life. A prospective registry was conducted for 24 months in 5 European countries and analyzed by the European Association of Urology Research Foundation. MATERIALS AND METHODS: Previously untreated and treated patients were enrolled to the registry in both primary care and urology referral centers in France, Germany, Italy, Spain and the UK. RESULTS: Overall, 2,175 patients were enrolled with 1,838 analyzed, consisting of 575 previously untreated lower urinary tract symptoms-benign prostatic enlargement patients (no alpha blockers for at least 1 month or no 5-alpha reductase inhibitors for at least 6 months) and 1,263 previously treated patients. During the registry 90% of patients adhered to the prescribed regimen. After 24 months, 70% of previously untreated and 42% of previously treated patients experienced symptom improvement (International Prostate Symptom Score [IPSS] reduction of ≥3 points). Symptomatic patients (IPSS ≥8) remained in both groups (59% in previously untreated and 61% in previously treated), with greater symptom deterioration (IPSS increase ≥3 points) in 18.9% in previously treated vs 7.8% in previously untreated patients. Both clinical lower urinary tract symptoms-benign prostatic enlargement progression and surgery rates were similar in untreated vs treated groups at 16% vs 17% and 5% vs 7%, respectively, at 24 months. CONCLUSIONS: This prospective registry confirmed lower urinary tract symptoms-benign prostatic enlargement pharmacological treatment effectiveness in a real-world setting, with low clinical progression observed in about 1 in 6 patients and lower surgery rates below 1 in 20, by 24 months.</p>}},
author = {{Tubaro, Andrea and Speakman, Mark and de la Taille, Alexandre and Martínez-Piñeiro, Louis and Berges, Richard and Patel, Anup and Bjartell, Anders and Caris, Christien and Witjes, Wim}},
issn = {{1527-3792}},
keywords = {{drug therapy; prostatic hyperplasia; registries}},
language = {{eng}},
number = {{4}},
pages = {{1145--1152}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{The Journal of urology}},
title = {{A European Registry Evaluating Symptomatic Effectiveness of Pharmacologically Treated Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Enlargement : Lessons Learned}},
url = {{http://dx.doi.org/10.1097/JU.0000000000001506}},
doi = {{10.1097/JU.0000000000001506}},
volume = {{205}},
year = {{2021}},
}